. Key eligibility and exclusion criteria Eligibility criteria; 1. Hospital systolic blood pressure (SBP) is 130 mmHg or more but less than 160 mmHg and diastolic blood pressure (DBP) is less than 100 mmHg 2. Hospital DBP 80 is mmHg or more but less than 100 mmHg and SBP is less than 160 mmHg 3. Home SBP is 125 mmHg or more but less than 155 mmHg and DBP is less than 95 mmHg 4. Home DBP is 75 mmHg or more but less than 95 mmHg and SBP is less than 155 mmHg Key exclusion criteria; 1. Subjects who are under treatment and medication for hypertension.
12. Subjects who regularly take medicine, functional foods and/or supplements (anthocyanin, lutein, astaxanthin, blueberry, beta-carotene, vitamin, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) etc.) that would affect the visual fatigue.
13. Heavy smokers, alcohol addicts or subjects with irregular lifestyles. 14. Subjects who donate either 400 ml of whole blood within 12 weeks or 200 ml of whole blood within 4
weeks or blood components within 2 weeks prior to the start of this study.
15. Subjects who are pregnant or expected to be pregnant, or lactating during the study.
16. Subjects who participated in other clinical trials within the last month prior to the current clinical trial.
17. Any other medical reasons judged by the principal investigator. 90.6 ± 13.5 94.2 ± 16.9 95.8 ± 20.0 95.1 ± 18.7 Placebo 90.2 ± 11.3 92.0 ± 10.9 91.6 ± 11.0 93.0 ± 11.1 Glycoalubulin (%) "Yabukita" 14.6 ± 1.9 14.3 ± 2.0 14.0 ± 1.9 14.0 ± 1.9 "Sunrouge" 14.8 ± 1.8 14.5 ± 2.0 14.2 ± 2.1 14.3 ± 2.0 Placebo 13.9 ± 1.1 13.8 ± 1.1 13.5 ± 1.1 13.6 ± 1.1 Complete blood count WBC (x10 3 /mL) "Yabukita" 5.6 ± 2.1 5.5 ± 1.4 5.8 ± 1.7 5.3 ± 1.4 "Sunrouge" 5.5 ± 1.5 5.7 ± 1.7 5.6 ± 1.7 5.9 ± 1.3 Placebo 5.4 ± 1.8 5.5 ± 1.6 5.6 ± 2.1 5. "Yabukita" 14.1 ± 1.5 14.4 ± 1.5 14.1 ± 1.5 14.2 ± 1.6 "Sunrouge"
14.1 ± 1.5 14.1 ± 1.5 14.0 ± 1.5 13.9 ± 1.5 Placebo 13.9 ± 1.3 13.9 ± 1.2 13.9 ± 1.4 14.0 ± 1.4 Ht (%) "Yabukita" 42.8 ± 4.1 44.0 ± 4.3 43.7 ± 4.2 43.5 ± 4.3 "Sunrouge"
42.4 ± 3.6 42.9 ± 3.9 42.8 ± 3.9 42.5 ± 3.7 Placebo 42.0 ± 3.4 42.4 ± 3.1 42.6 ± 3.6 42.7 ± 3.8
Plt (x10 4 /mL) "Yabukita" 23.3 ± 4.1 23.9 ± 3.9 24.6 ± 4.7 24.4 ± 4.4 "Sunrouge" 23. "Yabukita" 6.5 ± 2.3 6.1 ± 2.3 6.2 ± 2.4 6.2 ± 2.4 "Sunruge" 6.8 ± 2.4 6.4 ± 2.4 6.5 ± 2.6 6.6 ± 2.4 Placebo 7.2 ± 2.6 7.0 ± 2.7 7.1 ± 2.5 7.2 ± 2.4 TP (mg/dL) "Yabukita" 7.2 ± 0.4 7.4 ± 0.3 7.3 ± 0.4 7.3 ± 0.4 "Sunruge"
7.4 ± 0.4 7.5 ± 0.5 7.4 ± 0.4 7.4 ± 0.5 Placebo 7.3 ± 0.4 7.4 ± 0.3 7.3 ± 0.4 7.3 ± 0.4 Albumin (mg/dL) "Yabukita" 4.6 ± 0.3 4.7 ± 0.3 4.6 ± 0.3 4.6 ± 0.3 "Sunruge" 4.7 ± 0.2 4.7 ± 0.2 4.6 ± 0.2 4.6 ± 0.3 Placebo 4.6 ± 0.3 4.7 ± 0.2 4.6 ± 0.3 4.6 ± 0.2 A/G ratio "Yabukita" 1.7 ± 0.2 1.8 ± 0.2 1.7 ± 0.2 1.8 ± 0.2 "Sunruge"
1.7 ± 0.2 1.8 ± 0.2 1.7 ± 0.2 1.7 ± 0.2 Placebo 1.8 ± 0.3 1.8 ± 0.2 1.7 ± 0.2 1.7 ± 0.2 T-Bil (mg/dL) "Yabukita" 0.7 ± 0.3 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.3 "Sunruge" 0.8 ± 0.3 0.7 ± 0.3 0.7 ± 0.3 0.7 ± 0.3 Placebo 0.8 ± 0.2 0.7 ± 0.3 0.6 ± 0.2 0.7 ± 0.3 Renal metabolism BUN (mg/dL) "Yabukita" 12.8 ± 3.6 12.1 ± 2.8 12.5 ± 2.8 12.6 ± 3.0 "Sunruge" 13.2 ± 2.6 11.7 ± 2.3 12.2 ± 2.5 12.3 ± 2.6 Placebo 12.9 ± 2.8 12.0 ± 2.4 13.1 ± 3.0 12.8 ± 2.9 CRE (mg/dL) "Yabukita" 0.8 ± 0. 
